Craig Kevin James 4

What Happened
Craig Kevin James, Chief Medical Officer of AtaiBeckley Inc. (ATAI), exercised stock options to acquire a total of 100,000 shares (76,224 shares at $1.18 and 23,776 shares at $1.50) for a total cash exercise cost of $125,608. On the same day (Mar 20, 2026) he sold 100,000 shares in the open market for aggregate gross proceeds of $355,000 (weighted average price reported as $3.55; individual sale prices ranged $3.52–$3.60). The Form 4 also reports the corresponding derivative interests (the exercised options) as disposed (reported at $0).

Key Details

• Transaction date: March 20, 2026; Form 4 filed March 24, 2026 (filed within the two-business-day requirement).
• Option exercises acquired: 76,224 shares @ $1.18 = $89,944 and 23,776 shares @ $1.50 = $35,664 (total cash paid $125,608).
• Open-market sale: 100,000 shares @ weighted avg $3.55 = $355,000 (sales ranged $3.52–$3.60). Reporting person can provide exact breakdown per price on request (footnote).
• Shares owned after transaction: Not specified in the filing.
• Notable footnotes: Transactions were carried out pursuant to a Rule 10b5-1 trading plan adopted Dec 19, 2025 (F1). Vesting schedules for the options are noted (25% cliff then monthly vesting over 36 months) (F2, F3). Sale price is a weighted average; full per-price breakdown available on request (F4).
• Transaction codes: M = exercise/conversion of derivative (options); S = sale.

Context

• The filing shows options were exercised and an equal number of shares were sold the same day, indicating the exercised shares were not retained. This is commonly executed as a cashless exercise/sale pattern, but the filing itself only reports the mechanical steps (exercise and sale).
• The trades were made under a pre-established 10b5-1 plan, which is designed to allow insiders to sell shares according to a preset schedule and can reduce concerns about timing-based insider trading.
• These entries are factual disclosures of insider activity and do not by themselves indicate the insider’s view on the company’s prospects.